Glucose Fresenius Kabi France

Glucose Fresenius Kabi France is an intravenous solution that contains glucose monohydrate as its sole active ingredient. Manufactured by Fresenius Kabi in France, the product is supplied as a sterile liquid for parenteral administration. It is formulated to deliver a readily available source of carbohydrate and contributes to fluid volume when infused. The solution is used in clinical settings for fluid and electrolyte replacement and as caloric supplementation.

Glucose Fresenius Kabi France is indicated for several therapeutic purposes where intravenous carbohydrate delivery is required.

- Fluid and electrolyte replacement in patients unable to maintain oral intake. - Caloric supplementation as part of total parenteral nutrition (TPN) regimens. - Support of blood glucose levels during peri‑operative fasting. - Management of hypoglycemia when rapid intravenous glucose is needed. - Provision of an energy source during critical illness or trauma when oral feeding is delayed.

When administered intravenously, glucose solutions can be associated with a range of adverse reactions, most of which are related to the infusion itself or metabolic changes.

Common: - Transient hyperglycemia, especially in patients with impaired insulin response. - Local irritation or phlebitis at the infusion site. - Mild electrolyte shifts, such as a temporary decrease in serum potassium. - Nausea or abdominal discomfort if infused rapidly.

Serious: - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible individuals. - Fluid overload resulting in pulmonary edema, particularly in patients with cardiac or renal dysfunction. - Hypersensitivity reactions, including rash, urticaria, or anaphylaxis. - Hyperosmolar hyperglycemic state in patients with uncontrolled diabetes.

Clinicians should evaluate patient-specific factors before initiating therapy with Glucose Fresenius Kabi France to minimize risks.

- Assess baseline blood glucose and adjust infusion rate in diabetic or hyperglycaemic patients. - Monitor fluid balance and signs of overload in individuals with heart failure, renal impairment, or hepatic disease. - Use caution in patients with known hypersensitivity to glucose solutions or excipients. - Verify correct catheter placement and patency to reduce the risk of extravasation. - Avoid rapid bolus administration unless specifically indicated for acute hypoglycemia. - Consider electrolyte status, particularly potassium and sodium, before and during infusion.

Glucose solutions may interact with other intravenous medications or affect the pharmacokinetics of concurrently administered drugs.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring. - Simultaneous infusion of potassium chloride in concentrations that may precipitate when mixed with glucose solutions. - Use with medications that require a strict fluid restriction, such as certain diuretics, without adjusting total volume.

Use with caution: - Concurrent administration of calcium‑containing solutions, which can increase the risk of precipitation. - Infusion of other hyperosmolar solutions that may exacerbate hyperglycaemia. - Use in patients receiving vasopressors, as fluid shifts can influence hemodynamic stability.